TAM
ESPR

Tocqueville Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Tocqueville Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-87,000
Closed -$238K – 563
2026
Q1 		$238K Sell
87,000
-20,000
-19% -$63.3K ﹤0.01% 511
2025
Q4 		$396K Buy
107,000
+16,000
+18% +$51.7K 0.01% 480
2025
Q3 		$241K Buy
91,000
+27,500
+43% +$53.2K ﹤0.01% 520
2025
Q2 		$62.5K Sell
63,500
-1,500
-2% -$1.5K ﹤0.01% 531
2025
Q1 		$93.6K Sell
65,000
-5,000
-7% -$9.21K ﹤0.01% 507
2024
Q4 		$154K Sell
70,000
-2,500
-3% -$5.83K ﹤0.01% 530
2024
Q3 		$120K Sell
72,500
-5,000
-6% -$10.1K ﹤0.01% 518
2024
Q2 		$172K Buy
77,500
+37,750
+95% +$88.8K ﹤0.01% 508
2024
Q1 		$107K Buy
+39,750
New +$96.6K ﹤0.01% 524
2020
Q3 		– Sell
-5,500
Closed -$282K – 660
2020
Q2 		$282K Buy
+5,500
New +$230K 0.01% 574
2020
Q1 		– Sell
-5,500
Closed -$328K – 656
2019
Q4 		$328K Buy
+5,500
New +$247K ﹤0.01% 634
2018
Q2 		– Sell
-2,975
Closed -$215K – 832
2018
Q1 		$215K Buy
+2,975
New +$218K ﹤0.01% 772

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Tocqueville Asset Management's ESPR Position: Q2 2026 in Review

Tocqueville Asset Management sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 87,000 shares — an estimated $238K sold.

Tocqueville Asset Management first reported a position in ESPR in Q1 2018 and held it in 12 quarters. The position peaked at $396K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Tocqueville Asset Management reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Tocqueville Asset Management sold 87,000 Esperion Therapeutics shares in Q2 2026, an estimated $238K.
  • Tocqueville Asset Management first reported a position in Esperion Therapeutics in Q1 2018 and held it in 12 quarters.
  • Tocqueville Asset Management's Esperion Therapeutics position peaked at $396K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Tocqueville Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.